Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY
Status:
Terminated
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The outcome of HMA-refractory patients with MDS or AML is dismal with a median survival of 5
months after failure, representing a significant unmet medical need due to the very limited
treatment options. In this context, a specific targeting of the leukemic stem cell (LSC)
seems a promising option to selectively combat the leukemic progenitor cells. In fact, CD123
is overexpressed in AML and MDS progenitors making it an attractive target for
immunotherapy-based approaches. JNJ-56022473 is a promising compound that has been engineered
with regard to this strategy and the current phase II trial has the aim to evaluate the
overall hematological response rate at 3 months in HMA refractory/relapsed AML and MDS
patients.